MD FACP - Crispr Therapeutics Chief Officer
| CRSP Stock | USD 53.29 2.24 4.03% |
Executive
MD FACP is Chief Officer of Crispr Therapeutics AG
| Age | 50 |
| Address | Baarerstrasse 14, Zug, Switzerland, 6300 |
| Phone | 41 41 561 32 77 |
| Web | https://www.crisprtx.com |
Crispr Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0622) % which means that it has lost $0.0622 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0817) %, meaning that it created substantial loss on money invested by shareholders. Crispr Therapeutics' management efficiency ratios could be used to measure how well Crispr Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/09/2024, Return On Tangible Assets is likely to drop to -0.07. In addition to that, Return On Capital Employed is likely to grow to -0.1. As of 05/09/2024, Total Current Liabilities is likely to drop to about 63.5 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 1.3 BSimilar Executives
| Showing other executives | EXECUTIVE Age | ||
| Daniel Poon | Caribou Biosciences | N/A | |
| Cindy Tahl | Fate Therapeutics | 51 | |
| David MD | Intellia Therapeutics | 69 | |
| JD Esq | Caribou Biosciences | 69 | |
| Gerald Underwood | Regeneron Pharmaceuticals | N/A | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| Timothy MBA | Caribou Biosciences | 54 | |
| Derek Hicks | Intellia Therapeutics | 50 | |
| Dallan Murray | Sarepta Therapeutics | N/A | |
| Meg Dodge | Krystal Biotech | N/A | |
| Joan MBA | Verve Therapeutics | 55 | |
| Christine Wilson | Krystal Biotech | N/A | |
| Manmohan Singh | Beam TherapeuticsInc | N/A | |
| Kirsten Dupuis | AVROBIO | N/A | |
| Linda Burkly | Editas Medicine | N/A | |
| David Chien | Krystal Biotech | N/A | |
| Jim MBA | Fate Therapeutics | N/A | |
| Charlene JD | Editas Medicine | N/A | |
| Kathryn Romano | Krystal Biotech | 42 | |
| Diane Berry | Sarepta Therapeutics | N/A | |
| John Karakkal | Krystal Biotech | N/A | |
Management Performance
| Return On Equity | -0.0817 | ||||
| Return On Asset | -0.0622 |
Crispr Therapeutics Leadership Team
Elected by the shareholders, the Crispr Therapeutics' board of directors comprises two types of representatives: Crispr Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crispr. The board's role is to monitor Crispr Therapeutics' management team and ensure that shareholders' interests are well served. Crispr Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crispr Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samarth Kulkarni, Chief Business Officer | ||
| Susan Kim, Vice Relations | ||
| Craig Mello, Scientific Member | ||
| Lawrence Klein, Chief Officer | ||
| Chad Cowan, Scientific Founder | ||
| Rodger MD, Chairman Founder | ||
| Daniel Anderson, Scientific Member | ||
| Emmanuelle Charpentier, CoFounder Member | ||
| Raju Prasad, Chief Officer | ||
| Matthew MD, Scientific Member | ||
| Stephen Kennedy, Head Operations | ||
| James Kasinger, General Counsel, Secretary to the Board of Directors | ||
| Brendan MBA, CFO VP | ||
| MD FACP, Chief Officer | ||
| Shaun Foy, Founder |
Crispr Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Crispr Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0817 | ||||
| Return On Asset | -0.0622 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 3 B | ||||
| Shares Outstanding | 84.88 M | ||||
| Shares Owned By Insiders | 1.86 % | ||||
| Shares Owned By Institutions | 68.73 % | ||||
| Number Of Shares Shorted | 14.74 M | ||||
| Price To Earning | 17.33 X |
Crispr Therapeutics Investors Sentiment
The influence of Crispr Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Crispr. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Crispr Therapeutics' public news can be used to forecast risks associated with an investment in Crispr. The trend in average sentiment can be used to explain how an investor holding Crispr can time the market purely based on public headlines and social activities around Crispr Therapeutics AG. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Crispr Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Crispr Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Crispr Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Crispr Therapeutics.
Crispr Therapeutics Implied Volatility | 169.04 |
Crispr Therapeutics' implied volatility exposes the market's sentiment of Crispr Therapeutics AG stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Crispr Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Crispr Therapeutics stock will not fluctuate a lot when Crispr Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Crispr Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Crispr Therapeutics' short interest history, or implied volatility extrapolated from Crispr Therapeutics options trading.
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crispr Stock
| 0.49 | VTYX | Ventyx Biosciences | PairCorr |
| 0.42 | GILD | Gilead Sciences | PairCorr |
| 0.41 | VIGL | Vigil Neuroscience Trending | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 4.686 | Quarterly Revenue Growth 33.5 K | Return On Assets (0.06) | Return On Equity (0.08) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.